INDUSTRY REVIEWS

Because of our extensive experience and exclusive focus in health care and life sciences, we have amassed a wealth of industry and scientific knowledge. We draw on that in identifying market segments that are poised to grow significantly. These are often areas where technologies are emerging to address unmet customer needs. When we focus on one of these markets, we perform a bottom-up analysis to develop quantifiable insights into that market’s trends and drivers. These insights allow our clients to confidently make better decisions regarding which markets to enter, and how best to penetrate the target marketplaces. We often develop perspectives that are unique and insights that are innovative. You are invited to review our presentation decks to see examples of our work.

Strategic Review of Cell Therapy Market

Date Released: Dec 8, 2008 Cell Therapy promises to prevent, treat, and/or cure human diseases through the administration of ex vivo modified cells. Today, Cell Therapy is already having clinical impact in areas such as cancer and wound treatment where it is being used as the standard of care to treat some diseases. The future of the Cell Therapy market will primarily be driven by the growth of the Stem Cell segment, which itself is triggered by the forthcoming launch of novel therapies for various neurological disorders, cancer, and diabetes applications. The goal of this presentation is to illustrate the current state of Cell Therapy and also to highlight some important unmet needs and key success factors that current and potential market players must address to be successful in this market.
Strategic Growth Opportunities in Functional Foods and Beverages

Date Released: Dec 3, 2008 Functional Foods are foods that deliver health benefits beyond basic nutrition. The science has advanced enormously, and so has the technology to deliver these powerful nutrients within a food or beverage that still tastes good. In addition, consumers now believe that functional foods can play a role in managing their health and in the prevention of health problems. The convergence of those developments is making this an area of great excitement within the field of Health & Wellness. This presentation provides an overview of the field, gives examples of functional food ingredients as well as finished products, shows examples of successful and unsuccessful market launches, and touches on many of the components of success in this emerging industry.
Impact of DNA Microarrays on Molecular Diagnostics

Date Released: Oct 21, 2008 DNA microarrays are a powerful molecular diagnostic tool that facilitates multiplex, simultaneous analysis of tens to hundreds of markers that guide the identification of disease and its management. DNA microarrays have begun to move into mainstream clinical diagnostics. This presentation will review application areas of microarrays in molecular diagnostics, the market size, future growth prospects, key growth drivers, barriers, and other market forces such as regulatory and reimbursement challenges.



Medical Devices: Cardiovascular Overview

Date Released: Oct 6, 2008 At close to $200 B in size and growing, the Medical Device market represents one of the largest, most diverse and most robust healthcare sectors. Despite being dominated by U.S. and Western Europe markets, the worldwide medical device market is being driven by global healthcare trends such as the increase in decentralization of healthcare and increasingly obese, diabetic and elderly populations. This presentation provides a focus on cardiovascular health; traditionally one of the largest, most innovative and more competitive areas of the medical device market.
Scientia Decentralization of Healthcare Presentation

Date Released: Sep 18, 2008 The increasing migration of healthcare from centralized, core hospital locations to more point-of-care settings such as emergency rooms, outpatient clinics, rapid and urgent care clinics, and the home. A Decentralized Healthcare system aims to improve overall implementation of healthcare programs, provide uniformity of healthcare standards across rural and urban areas and lower costs by moving to more streamlined and efficient programs
Scientia Panelists Decentralization of Healthcare Presentation

Date Released: Sep 18, 2008 Presentations by: Michael Critelli - Executive Chairman of Pitney Bowes Inc., and Chairman of the Board, Dossia Alicia Ledlie - Senior Director - Health Business Development of Wal-Mart Stores Inc John Bishop - CEO, Cepheid The increasing migration of healthcare from centralized, core hospital locations to more point-of-care settings such as emergency rooms, outpatient clinics, rapid and urgent care clinics, and the home. A Decentralized Healthcare system aims to improve overall implementation of healthcare programs, provide uniformity of healthcare standards across rural and urban areas and lower costs by moving to more streamlined and efficient programs.
The Future of Cancer Diagnostics

Date Released: Aug 25, 2008 Cancer is a complex, multi-factorial disease comprising more than 100 similar diseases. Current diagnostic tools, including various blood marker based immuonoassays, imaging techniques, and biopsy analysis, provide valuable information but remain effective only when the tumor frequency is greater than 1% to 10%. New molecular tests such as breast cancer prognosis are changing the cancer care paradigm by providing critically needed information early in the care cycle and reducing healthcare costs. This session focuses on such high value molecular tests for solid tumors that improve disease outcome by providing early detection, prognostic information, and stratify responsiveness to therapy.



Future of Healthcare - Introduction of Clay Christensen

Date Released: Apr 2, 2008 This presentation briefly introduces the concepts of Clay Christensen who discusses the following: In the absence of the ability to precisely define a disease, the care of patients is best undertaken by highly skilled professionals, whose intuition is based on deep experience. This describes the history of health care, and we call this the practice of intuitive medicine. Molecular cell biology holds the promise of transforming medical practice into a new phase that we call precision medicine. It promises to dramatically reduce cost and increase the predictable effectiveness of therapy.
Musculoskeletal Market Strategic Review

Date Released: Mar 10, 2008 The Musculoskeletal (MSK) market is concerned with the motion and scaffold of the human body (i.e. bones, muscles, tendons, etc.) and is one of many areas of the healthcare industry poised to benefit from the developed world’s increasingly aging population. This presentation highlights the main trends and drivers of the overall MSK market and provides strategic insight into constituent sub-markets. Within the MSK market, we believe the Orthobiologics market is the most attractive segment based on market growth and lower competitive intensity.
Wound Care Market Strategic Review

Date Released: Feb 7, 2008 The wound care market represents an extremely diverse group of products and therapies, ranging from biological growth factors to wound therapy surfaces such as advanced hospital beds and chairs. For the most part, the wound care market has matured, however, there still remain a variety of high-growth, specialized markets that present good opportunites for investment. This presentation outlines the key drivers and trends of the overall wound care market while also providing insight into emerging trends and technologies that are being rapidly advanced by the industry’s increasing understanding and application of biological processes.
Personalized Medicine Strategic Review

Date Released: Dec 19, 2007 Personalized medicine tests have had a large impact on the oncology care cycle and greatly influenced therapeutic decisions. Today, as many pharmaceutical companies are plagued by fewer drug approvals and upcoming patent expirations, seeking opportunities within personalized medicine will be one way to bolster sales of therapeutics. We believe oncology therapeutics will continue to be one of the main adopters of personalized medicine and we recommend pharmaceutical companies act accordingly to strategically position themselves within the personalized medicine landscape as well as evaluate any potential influence personalized medicine might have on sales of therapeutics. The goal of this presentation is to review the various types of Molecular Diagnostic based personalized medicine tests and assess their influence on oncology patient care and oncology therapeutics.
In Vitro Diagnostics Strategic Review

Date Released: Dec 18, 2007 The IVD market is a modest growth market with several segments that show different growth prospects. The overall industry outlook is very positive - driven by favorable demographics, health care cost pressures, industry consolidation, and new high value products. This presentation reviews the IVD industry dynamics, key growth drivers, and market forces such as emergence of rapid clinics that will change the delivery of IVD and patient care.
Molecular Diagnostics Strategic Review

Date Released: Dec 17, 2007 The purpose of this presentation is to highlight the specific market segment of the in vitro diagnostics market called molecular diagnostics. This presentation includes all the accepted clinical molecular diagnostic tests worlds wide that are currently used today, and explores new tests that are on the clinical horizon. It reviews the instruments and their reagents and supplies as utilized in hospital and commercial labs, clinics, and doctors' offices on a world wide basis.



Life Science Tools and Technologies Review

Date Released: Dec 17, 2007 Life Science Tools and Technologies presentation has been assembled by reviewing every major life science/analytical instrument technology and major reagent in the industry. Scientia Advisors regularly reviews market sizing, growth rates, and detailed analyses for this market.
Strategic Review of Point-of-Care Diagnostics

Date Released: Jul 5, 2007 The purpose of this presentation is to describe the specific market segment of the in vitro diagnostics market called point of care testing (POCT). It examines these clinical measurement devices and their reagents and supplies as utilized in hospitals, clinics and doctors’ offices. An analysis of analytes that are related to the common chemical constituents of blood, plasma or serum at the point of care of the patient is addressed. Moreover, the presentation defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories.
Challenges Posed by Combination Medical Products

Date Released: Jun 22, 2007 The convergence of the biological revolution with medical devices holds the promise of a new stream of innovations. Many medical device companies are grappling with how to manage product innovation and development so as to take advantage of the biological revolution. The goal of this brief presentation is to explore the challenges and opportunities for device companies that this convergence presents.



The Diabetes Circle of Care

Date Released: May 24, 2007 Diabetes is the seventh-leading cause of death, and is on the rise due to increasing obesity in both developed and developing countries. Scientia's review of the diabetes market provides an overview and forecasts of the overall diabetes care life cycle and discusses the future of the diabetes circle of care. The diabetes circle of care consists of predisposition testing, diagnosis, disease treatment, monitoring, and disease management/lifestyle . This review does not cover treatment & monitoring of complications associate with diabetes and lifestyle management options associated with the disease.

The review contains comprehensive details on current & emerging features in each component of the diabetes care cycle including:
  • Tests employed for diabetes diagnosis & monitoring
  • Therapeutic options for treatment of diabetes by drug classes
  • Medical device & delivery options for diabetes
Bookmark and Share